PSMA-targeted theranostic nanoplex for prostate cancer therapy

ACS Nano

Volumn 6, Issue 9, 2012, Pages 7752-7762

  Chen, Zhihang ^a,b   Penet, Marie France ^a   Nimmagadda, Sridhar ^a,b   Li, Cong ^a   Banerjee, Sangeeta R ^a   Winnard, Paul T ^a   Artemov, Dmitri ^a,b   Glunde, Kristine ^a,b   Pomper, Martin G ^a,b   Bhujwalla, Zaver M ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

prodrug enzyme therapy; prostate cancer; PSMA; siRNA therapy; theranostic imaging

Indexed keywords

5-FLUOROCYTOSINE; 5-FLUOROURACIL (5-FU); CELL SURFACES; CHOLINE KINASE; CYTOTOXIC; CYTOTOXIC DRUGS; DOWN-REGULATION; ENZYME THERAPY; EXPRESSION LEVELS; IMMUNE RESPONSE; MULTIMODAL IMAGING; MULTIMODALITY IMAGING; NON-INVASIVE IMAGING; NORMAL TISSUE; PRODRUGS; PROOF OF PRINCIPLES; PROSTATE CANCERS; PROSTATE-SPECIFIC MEMBRANE ANTIGENS; PROTEOMIC PROFILING; PSMA; SINGLE-AGENT; SIRNA THERAPY; SMALL INTERFERING RNA (SIRNA); TARGET GENES; THERANOSTIC AGENTS; TREATMENT MODALITY;

CELL MEMBRANES; DIAGNOSIS; DISEASE CONTROL; DISEASES; ENZYMES; MONOPOLE ANTENNAS; RNA; TUMORS;

GENE THERAPY;

DIAGNOSTIC AGENT; NANOPARTICLE; PROSTATE SPECIFIC ANTIGEN;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; MALE; METABOLISM; METHODOLOGY; MOUSE; PROSTATE TUMOR; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MICE; NANOPARTICLES; ORGAN SPECIFICITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84866645930     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn301725w     Document Type: Article

References (51)

1. Hassett, M. J.; O'Malley, A. J.; Pakes, J. R.; Newhouse, J. P.; Earle, C. C. Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women with Breast Cancer J. Natl. Cancer Inst. 2006, 98, 1108-1117
2. Ladewski, L. A.; Belknap, S. M.; Nebeker, J. R.; Sartor, O.; Lyons, E. A.; Kuzel, T. C.; Tallman, M. S.; Raisch, D. W.; Auerbach, A. R.; Schumock, G. T. et al. Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs from 2000 to 2002: First Results from the Research on Adverse Drug Events and Reports Project J. Clin. Oncol. 2003, 21, 3859-3866
3. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis elegans Nature 1998, 391, 806-811
4. Meister, G.; Tuschl, T. Mechanisms of Gene Silencing by Double-Stranded RNA Nature 2004, 431, 343-349
5. Devi, G. R. siRNA-Based Approaches in Cancer Therapy Cancer Gene Ther. 2006, 13, 819-829
6. Davis, M. E.; Zuckerman, J. E.; Choi, C. H.; Seligson, D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Evidence of RNAi in Humans from Systemically Administered siRNA via Targeted Nanoparticles Nature 2010, 464, 1067-1070
7. Ofek, P.; Fischer, W.; Calderon, M.; Haag, R.; Satchi-Fainaro, R. In Vivo Delivery of Small Interfering RNA to Tumors and Their Vasculature by Novel Dendritic Nanocarriers FASEB J. 2010, 24, 3122-3134
8. Merkel, O. M.; Mintzer, M. A.; Librizzi, D.; Samsonova, O.; Dicke, T.; Sproat, B.; Garn, H.; Barth, P. J.; Simanek, E. E.; Kissel, T. Triazine Dendrimers as Nonviral Vectors for In Vitro and In Vivo RNAi: The Effects of Peripheral Groups and Core Structure on Biological Activity Mol. Pharmaceutics 2010, 7, 969-983
9. Liu, G.; Xie, J.; Zhang, F.; Wang, Z.; Luo, K.; Zhu, L.; Quan, Q.; Niu, G.; Lee, S.; Ai, H. et al. N -Alkyl-PEI-Functionalized Iron Oxide Nanoclusters for Efficient siRNA Delivery Small 2011, 7, 2742-2749
10. Zheng, D.; Giljohann, D. A.; Chen, D. L.; Massich, M. D.; Wang, X. Q.; Iordanov, H.; Mirkin, C. A.; Paller, A. S. Topical Delivery of siRNA-Based Spherical Nucleic Acid Nanoparticle Conjugates for Gene Regulation Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 11975-11980
11. Gary, D. J.; Lee, H.; Sharma, R.; Lee, J.-S.; Kim, Y.; Cui, Z. Y.; Jia, D.; Bowman, V. D.; Chipman, P. R.; Wan, L. et al. Influence of Nano-Carrier Architecture on In Vitro siRNA Delivery Performance and In Vivo Biodistribution: Polyplexes vs Micelleplexes ACS Nano 2011, 5, 3493-3505
12. Zheng, M.; Librizzi, D.; Kiliç, A.; Liu, Y.; Renz, H.; Merkel, O. M.; Kissel, T. Enhancing In Vivo Circulation and siRNA Delivery with Biodegradable Polyethylenimine-Graft-Polycaprolactone-Block-Poly(ethylene glycol) Copolymers Biomaterials 2012, 33, 6551-6558
13. Lee, H.; Lytton-Jean, A. K. R.; Chen, Y.; Love, K. T.; Park, A. I.; Karagiannis, E. D.; Sehgal, A.; Querbes, W.; Zurenko, C. S.; Jayaraman, M. et al. Molecularly Self-Assembled Nucleic Acid Nanoparticles for Targeted In Vivo siRNA Delivery Nat. Nanotechnol. 2012, 7, 389-393
14. Taratula, O.; Garbuzenko, O.; Savla, R.; Wang, Y. A.; He, H.; Minko, T. Multifunctional Nanomedicine Platform for Cancer Specific Delivery of siRNA by Superparamagnetic Iron Oxide Nanoparticles-Dendrimer Complexes Curr. Drug Delivery 2011, 8, 59-69
15. Kenny, G. D.; Kamaly, N.; Kalber, T. L.; Brody, L. P.; Sahuri, M.; Shamsaei, E.; Miller, A. D.; Bell, J. D. Novel Multifunctional Nanoparticle Mediates siRNA Tumour Delivery, Visualisation and Therapeutic Tumour Reduction in Vivo J. Controlled Release 2011, 149, 111-116
16. Xu, G.; McLeod, H. L. Strategies for Enzyme/Prodrug Cancer Therapy Clin. Cancer. Res. 2001, 7, 3314-3324
17. Russell, P. J.; Khatri, A. Novel Gene-Directed Enzyme Prodrug Therapies Against Prostate Cancer Expert Opin. Invest. Drugs 2006, 15, 947-961
18. Singh, Y.; Palombo, M.; Sinko, P. J. Recent Trends in Targeted Anticancer Prodrug and Conjugate Design Curr. Med. Chem. 2008, 15, 1802-1826
19. Jain, R. K. Transport of Molecules in the Tumor Interstitium: A Review Cancer Res. 1987, 47, 3039-3051
20. Fukumura, D.; Jain, R. K. Tumor Microvasculature and Microenvironment: Targets for Anti-Angiogenesis and Normalization Microvasc. Res. 2007, 74, 72-84
21. Kozikowski, A. P.; Nan, F.; Conti, P.; Zhang, J.; Ramadan, E.; Bzdega, T.; Wroblewska, B.; Neale, J. H.; Pshenichkin, S.; Wroblewski, J. T. Design of Remarkably Simple, Yet Potent Urea-Based Inhibitors of Glutamate Carboxypeptidase II (NAALADase) J. Med. Chem. 2001, 44, 298-301
22. Banerjee, S. R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Foss, C. A.; Green, G.; Fox, J. J.; Lupold, S. E.; Mease, R. C.; Pomper, M. G. Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate-Specific Membrane Antigen Angew. Chem., Int. Ed. 2011, 50, 9167-9170
23. Schulke, N.; Varlamova, O. A.; Donovan, G. P.; Ma, D.; Gardner, J. P.; Morrissey, D. M.; Arrigale, R. R.; Zhan, C.; Chodera, A. J.; Surowitz, K. G. et al. The Homodimer of Prostate-Specific Membrane Antigen Is a Functional Target for Cancer Therapy Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 12590-125905
24. Huang, X.; Bennett, M.; Thorpe, P. E. Anti-Tumor Effects and Lack of Side Effects in Mice of an Immunotoxin Directed Against Human and Mouse Prostate-Specific Membrane Antigen Prostate 2004, 61, 1-11
25. Malet-Martino, M.; Jolimaitre, P.; Martino, R. The Prodrugs of 5-Fluorouracil Curr. Med. Chem. Anticancer Agents 2002, 2, 267-310
26. Li, C.; Penet, M. F.; Winnard, P., Jr.; Artemov, D.; Bhujwalla, Z. M. Image-Guided Enzyme/Prodrug Cancer Therapy Clin. Cancer Res. 2008, 14, 515-522
27. Glunde, K.; Ackerstaff, E.; Mori, N.; Jacobs, M. A.; Bhujwalla, Z. M. Choline Phospholipid Metabolism in Cancer: Consequences for Molecular Pharmaceutical Interventions Mol. Pharmaceutics 2006, 3, 496-506
28. Glunde, K.; Jie, C.; Bhujwalla, Z. M. Molecular Causes of the Aberrant Choline Phospholipid Metabolism in Breast Cancer Cancer Res. 2004, 64, 4270-4276
29. Mori, N.; Glunde, K.; Takagi, T.; Raman, V.; Bhujwalla, Z. M. Choline Kinase Down-Regulation Increases the Effect of 5-Fluorouracil in Breast Cancer Cells Cancer Res. 2007, 67, 11284-11290
30. Janardhan, S.; Srivani, P.; Sastry, G. N. Choline Kinase: An Important Target for Cancer Curr. Med. Chem. 2006, 13, 1169-1186
31. Glunde, K.; Jacobs, M. A.; Bhujwalla, Z. M. Choline Metabolism in Cancer: Implications for Diagnosis and Therapy Expert Rev. Mol. Diagn. 2006, 6, 821-829
32. Li, C.; Wildes, F.; Winnard, P., Jr.; Artemov, D.; Penet, M. F.; Bhujwalla, Z. M. Conjugation of Poly- l -Lysine to Bacterial Cytosine Deaminase Improves the Efficacy of Enzyme/Prodrug Cancer Therapy J. Med. Chem. 2008, 51, 3572-3582
33. Li, C.; Winnard, P. T., Jr.; Takagi, T.; Artemov, D.; Bhujwalla, Z. M. Multimodal Image-Guided Enzyme/Prodrug Cancer Therapy J. Am. Chem. Soc. 2006, 128, 15072-15073
34. Li, C.; Penet, M. F.; Wildes, F.; Takagi, T.; Chen, Z.; Winnard, P. T.; Artemov, D.; Bhujwalla, Z. M. Nanoplex Delivery of siRNA and Prodrug Enzyme for Multimodality Image-Guided Molecular Pathway Targeted Cancer Therapy ACS Nano 2010, 4, 6707-6716
35. Pomper, M. G.; Musachio, J. L.; Zhang, J.; Scheffel, U.; Zhou, Y.; Hilton, J.; Maini, A.; Dannals, R. F.; Wong, D. F.; Kozikowski, A. P. 11C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase) Mol. Imaging 2002, 1, 96-101
36. Jackson, P. F.; Cole, D. C.; Slusher, B. S.; Stetz, S. L.; Ross, L. E.; Donzanti, B. A.; Trainor, D. A. Design, Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N -Acetylated α-Linked Acidic Dipeptidase J. Med. Chem. 1996, 39, 619-622
37. Marchal, C.; Redondo, M.; Padilla, M.; Caballero, J.; Rodrigo, I.; Garcia, J.; Quian, J.; Boswick, D. G. Expression of Prostate Specific Membrane Antigen (PSMA) in Prostatic Adenocarcinoma and Prostatic Intraepithelial Neoplasia Histol. Histopathol. 2004, 19, 715-718
38. Perner, S.; Hofer, M. D.; Kim, R.; Shah, R. B.; Li, H.; Moller, P.; Hautmann, R. E.; Gschwend, J. E.; Kuefer, R.; Rubin, M. A. Prostate-Specific Membrane Antigen Expression as a Predictor of Prostate Cancer Progression Hum. Pathol. 2007, 38, 696-701
39. Yao, V.; Parwani, A.; Maier, C.; Heston, W. D.; Bacich, D. J. Moderate Expression of Prostate-Specific Membrane Antigen, a Tissue Differentiation Antigen and Folate Hydrolase, Facilitates Prostate Carcinogenesis Cancer Res. 2008, 68, 9070-9077
40. Evans, M. J.; Smith-Jones, P. M.; Wongvipat, J.; Navarro, V.; Kim, S.; Bander, N. H.; Larson, S. M.; Sawyers, C. L. Noninvasive Measurement of Androgen Receptor Signaling with a Positron-Emitting Radiopharmaceutical That Targets Prostate-Specific Membrane Antigen Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 9578-9582
41. Hillier, S. M.; Maresca, K. P.; Femia, F. J.; Marquis, J. C.; Foss, C. A.; Nguyen, N.; Zimmerman, C. N.; Barrett, J. A.; Eckelman, W. C.; Pomper, M. G. et al. Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer Cancer Res. 2009, 69, 6932-6940
42. Greish, K. Enhanced Permeability and Retention of Macromolecular Drugs in Solid Tumors: A Royal Gate for Targeted Anticancer Nanomedicines J. Drug Target 2007, 15, 457-464
43. Wernicke, A. G.; Edgar, M. A.; Lavi, E.; Liu, H.; Salerno, P.; Bander, N. H.; Gutin, P. H. Prostate-Specific Membrane Antigen as a Potential Novel Vascular Target for Treatment of Glioblastoma Multiforme Arch. Pathol. Lab. Med. 2011, 135, 1486-1489
44. Kularatne, S. A.; Wang, K.; Santhapuram, H. K.; Low, P. S. Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing Ligand Mol. Pharmaceutics 2009, 6, 780-789
45. Longley, D. B.; Harkin, D. P.; Johnston, P. G. 5-Fluorouracil: Mechanisms of Action and Clinical Strategies Nat. Rev. Cancer 2003, 3, 330-338
46. Boussif, O.; Lezoualc'h, F.; Zanta, M. A.; Mergny, M. D.; Scherman, D.; Demeneix, B.; Behr, J. P. A Versatile Vector for Gene and Oligonucleotide Transfer into Cells in Culture and in Vivo: Polyethylenimine Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7297-7301
47. Petersen, H.; Fechner, P. M.; Martin, A. L.; Kunath, K.; Stolnik, S.; Roberts, C. J.; Fischer, D.; Davies, M. C.; Kissel, T. Polyethylenimine-Graft- Poly(ethylene glycol) Copolymers: Influence of Copolymer Block Structure on DNA Complexation and Biological Activities as Gene Delivery System Bioconjugate Chem. 2002, 13, 845-854
48. Chollet, P.; Favrot, M. C.; Hurbin, A.; Coll, J. L. Side-Effects of a Systemic Injection of Linear Polyethylenimine-DNA Complexes J. Gene. Med. 2002, 4, 84-91
49. Glunde, K.; Raman, V.; Mori, N.; Bhujwalla, Z. M. RNA Interference-Mediated Choline Kinase Suppression in Breast Cancer Cells Induces Differentiation and Reduces Proliferation Cancer Res. 2005, 65, 11034-11043
50. Krishnamachary, B.; Glunde, K.; Wildes, F.; Mori, N.; Takagi, T.; Raman, V.; Bhujwalla, Z. M. Noninvasive Detection of Lentiviral-Mediated Choline Kinase Targeting in a Human Breast Cancer Xenograft Cancer Res. 2009, 69, 3464-3471
51. Wu, E. X.; Tang, H.; Jensen, J. H. Applications of Ultrasmall Superparamagnetic Iron Oxide Contrast Agents in the MR Study of Animal Models NMR Biomed. 2004, 17, 478-483